Fifth Third Wealth Advisors LLC Acquires 746 Shares of Eli Lilly and Company (NYSE:LLY)

Fifth Third Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,536 shares of the company’s stock after purchasing an additional 746 shares during the period. Eli Lilly and Company accounts for 0.9% of Fifth Third Wealth Advisors LLC’s portfolio, making the stock its 18th largest position. Fifth Third Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $5,863,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Tidemark LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. grew its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the period. Frank Rimerman Advisors LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth approximately $37,000. Finally, St. Johns Investment Management Company LLC grew its position in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after purchasing an additional 37 shares during the period. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Bank of America reiterated a “buy” rating and set a $1,000.00 price target on shares of Eli Lilly and Company in a research note on Monday. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $812.72.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02. Following the sale, the insider now directly owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 789,704 shares of company stock worth $672,385,964. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY traded up $7.78 on Thursday, reaching $909.04. The company had a trading volume of 1,861,129 shares, compared to its average volume of 2,933,384. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock has a market capitalization of $863.96 billion, a PE ratio of 133.33, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36. The firm’s 50 day moving average price is $807.55 and its 200 day moving average price is $735.35. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $909.57.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.62 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.